Clinical trial
A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects
NCT02523391 is registered in ClinicalTrials.gov with Xention Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects
- Lead sponsor
- Xention Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2015
- Completion date
- November 30, 2015
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dyslipidaemia